TORNALATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TORNALATE (TORNALATE).
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
| Metabolism | Hepatic via sulfation and glucuronidation; also metabolized by catechol-O-methyltransferase (COMT). |
| Excretion | Primarily renal excretion of unchanged drug and metabolites; <10% fecal. Approximately 60-70% of a dose is recovered in urine as unchanged drug and glucuronide conjugates within 24 hours. |
| Half-life | Terminal elimination half-life is approximately 9-12 hours in healthy adults. May be prolonged in elderly or those with hepatic impairment, necessitating dose adjustment. |
| Protein binding | Approximately 70% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 1.4-2.1 L/kg, indicating extensive tissue distribution, particularly to the lungs. |
| Bioavailability | Inhalation: systemic bioavailability is about 20% due to pulmonary deposition and subsequent absorption; oral bioavailability is low (<5%) due to first-pass metabolism. |
| Onset of Action | Bronchodilation begins within 5-10 minutes following inhalation, with peak effect at 1-2 hours. |
| Duration of Action | Duration of bronchodilation is 8-12 hours, supporting twice-daily dosing for maintenance therapy. |
2 puffs (340 mcg) inhaled via oral inhalation 4 times daily; maximum 12 puffs/day.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; caution in severe hepatic impairment due to lack of data. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | Use with caution; initiate at lower end of dosing range due to potential for increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TORNALATE (TORNALATE).
| Breastfeeding | Excretion in human milk is unknown; M/P ratio not established. Beta-2 agonists likely present in low amounts. Consider that maternal asthma control is important; benefit of breastfeeding likely outweighs minimal risk if mother is stable. Monitor infant for irritability, tachycardia, or feeding difficulties. |
| Teratogenic Risk | TORNALATE (bitolterol mesylate) is a beta-2 adrenergic agonist. Limited human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: no known risk; second/third trimester: may cause fetal tachycardia, hypoglycemia, and hyperglycemia due to beta agonist activity. Risk of preterm labor and low birth weight with chronic use. Overall, consider risk-benefit; not a major teratogen. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to TORNALATE or any component"]
| Precautions | ["Paradoxical bronchospasm","Cardiovascular effects (tachycardia, arrhythmias)","Hypokalemia","Immediate hypersensitivity reactions"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, serum glucose, and potassium levels. Assess fetal heart rate and growth via ultrasound if used chronically. Monitor for signs of preterm labor. Pulmonary function tests to assess asthma control. |
| Fertility Effects | No significant effects on fertility reported in animal studies. In humans, no specific data; beta-2 agonists are not known to impair fertility. Uncontrolled asthma may reduce fertility; thus, controlling asthma with TORNALATE may indirectly improve fertility. |